Overview

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Status:
RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.
Phase:
PHASE3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.